Welcome to our dedicated page for Profound Medical SEC filings (Ticker: PROF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Profound Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Profound Medical's regulatory disclosures and financial reporting.
Profound Medical Corp. reported Q3 2025 results and highlighted liquidity risks. Revenue rose to $5.289 million, up 87% year over year, driven by U.S. capital sales and higher recurring revenue. Gross margin improved to 74% from 63% as manufacturing efficiency and mix shifted toward higher‑margin systems. Net loss was $7.977 million, narrowing from $9.365 million.
For the nine months ended September 30, 2025, revenue was $10.121 million and net loss totaled $34.395 million, with operating cash outflow of $31.641 million. Cash was $24.826 million and working capital was $31.586 million as of September 30, 2025. Long‑term debt was presented as current at $4.480 million due to a projected covenant breach by June 30, 2026 under the CIBC Credit Agreement. Management disclosed substantial doubt about the company’s ability to continue as a going concern and plans to seek additional financing. As of November 13, 2025, 30,193,592 common shares were outstanding.
The company continues remediation of a previously identified material weakness in revenue recognition controls.
Profound Medical Corp. (PROF) announced it has entered into an exclusive distribution and supply agreement with Getz Healthcare for its TULSA-PRO system in Australia and New Zealand. The company disclosed the news under Regulation FD, indicating a commercial channel partner will handle market distribution in these regions.
The announcement was provided via a press release furnished as Exhibit 99.1. As furnished information under Item 7.01, it is not deemed filed under Section 18 of the Exchange Act and is not incorporated by reference into other SEC filings.
Profound Medical Corp. (PROF) announced it entered into an exclusive distribution and supply agreement in Saudi Arabia with Al Faisaliah Medical Systems Co. covering its TULSA-PRO and Sonalleve technologies. The company disclosed the news via a press release furnished under Item 7.01 (Regulation FD).
The agreement designates a single distributor for these systems in Saudi Arabia, signaling a focused commercial pathway for Profound Medical’s prostate ablation (TULSA-PRO) and MR-guided therapeutic ultrasound (Sonalleve) platforms in that market. The press release was furnished as Exhibit 99.1.
Profound Medical Corp. reported under Regulation FD that it has regained exclusive distribution rights for its TULSA-PRO product in Canada from Knight Therapeutics Inc. The company announced the change in a press release dated November 10, 2025, which is furnished as Exhibit 99.1.
The Item 7.01 disclosure notes the press release is furnished, not filed, and is not incorporated by reference into other SEC filings.
Profound Medical Corp. filed a current report to note that it issued a press release on October 7, 2025 announcing certain preliminary unaudited financial results for the three months ended September 30, 2025 and providing a business update. The press release is furnished as Exhibit 99.1 under Item 2.02, which covers results of operations and financial condition. The company states that this information, including Exhibit 99.1, is furnished rather than filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings.
Profound Medical Corp. furnished an update on its recent performance by reporting that it issued a press release with unaudited financial results for the three- and six-month periods ended June 30, 2025. The company also used the release to provide a broader business update.
The press release is attached as Exhibit 99.1 and is furnished, not filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities filings unless specifically referenced. This 8-K is a disclosure vehicle pointing investors to that detailed financial and operational information.